第六届董事会第十八次会议决议公告 证券代码：300012 证券简称：华测检测 公告编号：2024-048 华测检测认证集团股份有限公司 一、会议以 7 票同意、0 票反对、0 票弃权，审议通过《2024 年第三季度报 告全文》 华测检测认证集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董 事 会 华测检测认证集团股份有限公司（以下简称"公司"）第六届董事会第十八次 会议于 2024 年 10 月 14 日发出会议通知，2024 年 10 月 24 日以现场结合通讯方式 召开。本次会议应参与董事 7 名，实际参与董事 7 名，分别为：万峰、申屠献忠、 钱峰、戚观成、程海晋、曾繁礼、刘志权。会议由董事长万峰主持，董事会会议 的举行和召开符合国家有关法律、法规及《公司章程》的规定。经充分讨论和审 议，会议形成决议如下： 二○二四年十月二十五日 本议案已经审计委员会审议通过，公司《2024 年第三季度报告全文》（公告 编号：2024-050）具体内容详见在巨潮资讯网的相关公告。 二、会议以 7 票同意、0 票反对、0 票弃权，审议通过《关于拟购买土 ...

第六届监事会第十三次会议决议公告 公司《2024 年第三季度报告全文》具体内容详见巨潮资讯网的相关公告。 特此公告！ 华测检测认证集团股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）第六届监事会第十三 次会议于 2024 年 10 月 14 日发出会议通知，2024 年 10 月 24 日以现场结合通讯方 式召开。本次会议应参加监事 3 人，实际参加监事 3 人，分别为：陈炜明、杜学 志、张渝民。本次会议召开符合《公司法》和《公司章程》的有关规定。会议由 公司监事会主席陈炜明先生主持，经与会监事认真审议，形成如下决议： 一、会议以 3 票同意、0 票反对、0 票弃权，审议通过《2024 年第三季度报告全 文》 监事会认为，公司董事会编制和审核的《2024 年第三季度报告全文》的程序 符合法律、行政法规、中国证监会和深交所的规定，报告的内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 证券代码：300012 证券简称：华测检测 公告编号：2024-049 华测 ...

[Table_MainInfo] 公司研究/机械工业/仪器仪表 证券研究报告 华测检测（300012）公司信息点评 2024 年 10 月 15 日 请务必阅读正文之后的信息披露和法律声明 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | |-------------------------------------------------------------------------------------| | 股票数据 | | 10 [ Table_StockInfo 月 14 日收盘价（元） ] | | 52 周股价波动（元） | | 总股本 / 流通 A 股（百万股） | | 总市值 / 流通市值（百万元） | | 相关研究 | | | | [Table_ReportInfo] 《 24Q2 毛利率同环比改善，期待医药医学板 块修复》 2024.08.13 | | 《预告 归母净利润同比增速转正，经营向 | | Q2 好》 | | 2024.07.10 《业绩短期承压，新领域布局加速，长期成长 | | 可期》 2024.05.09 市场表现 | -41.48% -29. ...

证券代码：300012 证券简称：华测检测 公告编号：2024-047 华测检测认证集团股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）于 2024 年 7 月 2 日 召开第六届董事会第十六次会议审议通过了《关于回购公司股份方案的议案》， 公司计划使用自有资金以集中竞价方式回购公司股份，回购的公司股份用于员工 持股计划或股权激励。本次拟回购股份数量为 200 万股-300 万股，回购股份价格 不超过人民币 16.83 元/股，按照回购数量上限 300 万股和回购价格上限 16.83 元/ 股的条件下测算，预计回购金额不超过 5,049 万元，具体回购股份的数量以回购 结束时实际回购的股份数量为准。本次回购实施期限为自公司董事会审议通过本 次回购股份方案之日起不超过 12 个月。具体内容详见公司 2024 年 7 月 3 日、2024 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）上披露的《关于回购公 司股份方案的公告》（公告编号：2024 ...

Group 1: Investor Relations Activities - The company conducted multiple investor relations activities from August 19 to September 27, 2024, including on-site research and conference calls, involving a total of 10 to 39 participants per event [1][2][3][4][5][6][7][8][9]. - Notable participants included major investment firms such as Point72, Temasek, and Goldman Sachs, indicating strong interest from institutional investors [2][5][6][7]. Group 2: Financial Performance and Strategy - The company reported a significant improvement in gross margin, with a year-on-year increase of 66.67% in cash dividend per share and a cash dividend rate (including buybacks) of 27.61%, totaling over 1 billion CNY in cumulative cash dividends [6][7]. - The management emphasized a focus on strategic investments in emerging sectors such as "dual carbon" services, biopharmaceuticals, and new energy vehicles, despite a slowing macroeconomic environment [6][7][8]. Group 3: Market Position and Competition - The company operates in a fragmented market with low concentration, where the top four global testing institutions hold a combined market share of only 9.2% [8][9]. - The competitive landscape remains challenging, but the company aims to leverage its operational efficiency and scale to capture a larger market share as smaller firms exit the market due to increased competition and regulatory pressures [8][9]. Group 4: Talent Development and Corporate Culture - The company places a strong emphasis on talent development, implementing various leadership training programs to enhance management capabilities across different levels [9]. - A transparent corporate culture and a commitment to integrity and innovation are highlighted as core competitive advantages that help the company build brand recognition and trust in the market [8][9].

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关法律、法规和规范性文件的规定，公司在回购期间应 当在每个月的前三个交易日内披露截至上月末的回购进展情况。现将公司截至上 月末的回购进展情况公告如下：截至 2024 年 8 月 31 日，公司通过回购专用证券 账户以集中竞价交易方式实施股份回购，回购股份数量为 400,000 股，占公司目 前总股本的 0.0238%，最高成交价为 10.49 元/股，最低成交价为 10.28 元/股， 成交均价 10.38 元/股，成交总金额为 415.23 万元（不含交易费用）。本次回购 符合《回购公司股份方案》及相关法律法规的规定。 二、其他说明 公司首次回购股份的时间、回购股份数量及集中竞价交易的委托时间均符合 证券代码：300012 证券简称：华测检测 公告编号：2024-046 华测检测认证集团股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华测检测认证集团股份有限公司（以下简称"公司"）于 2024 年 7 月 2 日 召开第六届董事会 ...

Financial Performance - In the first half of 2024, Huace achieved revenue of CNY 2.791 billion, a year-on-year increase of 9.20% [1] - Net profit attributable to shareholders reached CNY 437 million, up 1.97% year-on-year; non-recurring net profit was CNY 403 million, an increase of 4.74% [1] - The overall gross margin improved to 49.52% [1] - In Q2 2024, revenue was CNY 1.599 billion, a year-on-year growth of 11.14%; net profit was CNY 304 million, up 7.09% [1] Segment Performance - Life Sciences segment revenue was CNY 1.259 billion, a growth of 21.68% [2] - Industrial Testing segment revenue reached CNY 559 million, increasing by 13.80% [2] - Consumer Products Testing segment revenue was CNY 462 million, a decline of 3.88% [1] - Trade Assurance segment revenue was CNY 375 million, showing stable growth [1] Strategic Developments - Huace is focusing on digital transformation and has expanded its digital services across various sectors, including healthcare, finance, and education [2] - The company is actively pursuing opportunities in the dual carbon and ESG fields, contributing to its growth [5] - Huace has established a comprehensive service capability in the agricultural sector, enhancing its competitive edge [3] Challenges and Outlook - The medical and health services segment faced a decline in revenue, particularly in the pharmaceutical testing area, which is expected to recover in the long term [7] - The company is managing cash flow effectively, with a net cash flow from operating activities of CNY 22.21 million in the first half of 2024 [7] - Huace anticipates stable or improved performance across its product lines in the second half of 2024 [5]

Investment Rating - The report maintains a Neutral rating for the company [1][3][7]. Core Insights - The company reported a revenue of RMB 27.91 billion and a net profit of RMB 4.37 billion for the first half of 2024, reflecting a year-on-year growth of 9% and 2% respectively, which aligns with forecasts [1][3]. - The second quarter of 2024 saw revenue and net profit of RMB 15.99 billion and RMB 3.04 billion, showing a year-on-year increase of 11% and 7% respectively [1][3]. - The life sciences and industrial testing segments experienced steady growth, while the pharmaceutical and semiconductor sectors faced challenges [1][3][7]. - The gross margin improved by 2 percentage points in the second quarter, attributed to efficiency gains from digitalization and the expansion of higher-margin chemical testing services [1][3]. - The company anticipates a slight improvement in performance for the second half of 2024, driven by accelerated growth in traditional food and environmental testing [1][3]. Summary by Relevant Sections Financial Performance - For the first half of 2024, the company achieved a revenue of RMB 27.91 billion and a net profit of RMB 4.37 billion, with respective year-on-year growth rates of 9% and 2% [1]. - The second quarter results were RMB 15.99 billion in revenue and RMB 3.04 billion in net profit, with year-on-year growth of 11% and 7% [1][3]. Segment Performance - Life Sciences: Revenue grew by 22% year-on-year in the first half and 23% in the second quarter, driven by traditional food and environmental testing [1][3]. - Industrial Testing: Revenue increased by 14% year-on-year in the first half and 8% in the second quarter, supported by digitalization and carbon emission certification [3]. - Pharmaceutical Sector: Revenue declined by 34% year-on-year in the first half and 15% in the second quarter, although the decline rate narrowed in the second quarter [3]. Future Outlook - The company expects a decrease in revenue contribution from soil testing in the second half, but anticipates accelerated growth in traditional food and environmental testing [1][3]. - The management forecasts a stable growth of approximately 20% in the traditional consumer testing segment and a recovery in semiconductor testing [2][3]. Valuation - The report adjusts the earnings per share forecast for 2024-2027 upwards by 1% to 2%, reflecting the company's performance and outlook, with a 12-month target price raised to RMB 15.0, based on a 21x P/E ratio for 2025 [3][4].

Financial Data and Key Metrics Changes - In the first half of 2024, the company achieved revenue of 2.79 billion yuan, representing a year-on-year growth of 9.2%, and a net profit of 437 million yuan, with a year-on-year increase of 1.97% [1][3] Business Line Data and Key Metrics Changes - The Life Sciences segment generated revenue of 1.259 billion yuan, up 21.68% year-on-year [4][6] - The Industrial Testing segment reported revenue of 559 million yuan [4] - The Consumer Products segment saw revenue of 462 million yuan, a decline of 3.88% [5] - The Trade Assurance segment achieved revenue of 375 million yuan, a slight increase of 0.3% [5] - The Medical and Health segment's revenue was 136 million yuan, down 34.2% [5] - The Environmental segment is expected to maintain annual revenue between 300 million to 400 million yuan [1][15] Market Data and Key Metrics Changes - The company noted strong growth in the digital carbon reduction sector within the Industrial Testing segment [1][15] - The Medical Devices sector is projected to grow over 30% [21] Company Strategy and Development Direction - The company is focusing on digital transformation, lean management, and talent empowerment to enhance operational efficiency and achieve sustainable development [2] - The strategy includes a combination of organic growth and acquisitions to adjust strategic layouts and drive business growth [1][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the medium to long-term development of the Medical and Health segment despite current challenges, citing the aging population as a positive factor [7] - The company is taking systematic measures to manage accounts receivable and improve cash flow amid economic pressures [22] Other Important Information - The company is facing challenges with increased bad debts, particularly from government and state-owned enterprise clients, which has impacted profits [16] - The company is optimistic about the future performance of the Weishibo segment despite current losses [18] Q&A Session Summary Question: Does the company have a long-term strategic plan? - The company is committed to enhancing operational efficiency and organizational capabilities through digital transformation and talent empowerment [2] Question: How did the company perform in the first half of 2024? - The company reported strong performance with revenue of 2.79 billion yuan and net profit of 437 million yuan, indicating quality and sustainable growth [3] Question: What are the highlights of the Life Sciences segment? - The Life Sciences segment benefited from strong performance in soil testing and marine environment testing, achieving double-digit growth [6] Question: What is the outlook for the Medical and Health segment? - Despite current challenges, the company remains optimistic about the medium to long-term growth of the Medical and Health segment [7] Question: How is the company managing accounts receivable and cash flow? - The company is implementing systematic measures to control and improve accounts receivable, with cash flow expected to improve in the coming months [22]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company's performance in the first half of 2024 aligns with market expectations, driven by strong growth in the life sciences and industrial testing sectors [1][2] - The company has a forward-looking strategy focusing on emerging businesses and international expansion, which is expected to sustain long-term growth [1][2] Financial Performance Summary - In H1 2024, the company achieved total revenue of 2.79 billion yuan, a year-on-year increase of 9.2%, and a net profit attributable to shareholders of 440 million yuan, up 2.0% year-on-year [2][7] - The life sciences segment reported revenue of 1.26 billion yuan, growing 21.7% year-on-year, while the industrial testing segment saw revenue of 560 million yuan, up 13.8% year-on-year [2][7] - The gross profit margin for H1 2024 was 49.5%, with a slight year-on-year increase of 0.1 percentage points, while the net profit margin was 15.7%, down 1.5 percentage points year-on-year [2][7] Business Segment Performance - The life sciences and industrial testing segments showed strong performance, while the consumer products testing segment experienced a decline of 3.9% year-on-year [2][7] - The trade assurance segment grew by 9.3% year-on-year, while the pharmaceutical and medical services segment saw a significant decline of 34.2% year-on-year due to the base effect from nucleic acid testing [2][7] Future Outlook - The company is actively pursuing mergers and acquisitions to enhance its capabilities in strategic emerging fields such as semiconductor testing and low-altitude economy [1][2] - The internationalization strategy is progressing, with Singapore set as the overseas operational headquarters to expand into Southeast Asia and other regions [1][2] Earnings Forecast and Valuation - The report forecasts net profits attributable to shareholders for 2024, 2025, and 2026 to be 1.06 billion yuan, 1.23 billion yuan, and 1.43 billion yuan, respectively [1][2] - The current market capitalization corresponds to a price-to-earnings ratio of 19, 16, and 14 times for the years 2024, 2025, and 2026 [1][2]